Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop.
Hepatitis C virus common transmission routes and HCV coinfection is frequent in persons living with HIV. Liver enzyme elevation following the initiation of antiretroviral therapy is frequently seen in HIV-infected patients with chronic liver disease, particularly those with chronic hepatitis C. This complication may lead to treatment discontinuation, complicating HIV therapeutic management. Multiple factors influence the risk of liver toxicity under antiretroviral therapy, including the specific drug in use (e.g. use of full doses of ritonavir), and environmental factors (e.g. alcohol abuse). However a beneficial effect of antiretroviral therapy on liver disease has been supported by some studies. Despite increasing knowledge of HCV/HIV coinfection, there is no clear consensus on how to treat HIV in HCV-coinfected patients An Italian group of experts were invited to discuss in detail the current risks and implications of antiretroviral treatment in HIV-infected persons with chronic hepatitis C, and their main conclusions are summarized in this consensus document.
Carosi
Giampiero
G
Department of Infectious Disease, University of Brescia, Brescia, Italy.
Puoti
Massimo
M
Antonucci
Giovanni
G
De Luca
Andrea
A
Maserati
Renato
R
Torti
Carlo
C
Bonfanti
Paolo
P
Bonora
Stefano
S
Bruno
Raffaele
R
Gaeta
Giovanni Battista
GB
Antinori
Andrea
A
Monforte
Antonella d'Arminio
Ad
Orani
Anna
A
Sagnelli
Evangelista
E
Cargnel
Antonietta
A
Cauda
Roberto
R
Mazzotta
Francesco
F
Pastore
Giuseppe
G
Suter
Fredy
F
Vullo
Vincenzo
V
D019380:Anti-HIV Agents / Q000627:therapeutic use; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007558:Italy
D019380:Anti-HIV Agents; D044966:Anti-Retroviral Agents